Indivior Pharmaceuticals, Inc. Convertible Senior Notes Offering

Indivior Pharmaceuticals, Inc. has issued $500 million in aggregate principal amount of 0.625% Convertible Senior Notes due 2031. The offering also included an additional $50 million due to the full exercise of an option by the initial purchasers. These notes are senior, unsecured obligations and will accrue interest at a rate of 0.625% per annum, payable semi-annually. The notes mature on March 15, 2031, with conversion rights available under certain conditions, including a specific period from and after December 16, 2030. The initial conversion rate is 24.0033 shares of common stock per $1,000 principal amount, representing an initial conversion price of approximately $41.66 per share, a premium of 35.0% over the last reported sale price on March 12, 2026. The company has the option to redeem the notes under certain conditions, and noteholders may require repurchase upon a Fundamental Change. The company also used a portion of the proceeds to prepay outstanding principal, accrued interest, and fees under a prior Note Purchase Agreement dated November 4, 2024, leading to its termination.